<code id='DF10048580'></code><style id='DF10048580'></style>
    • <acronym id='DF10048580'></acronym>
      <center id='DF10048580'><center id='DF10048580'><tfoot id='DF10048580'></tfoot></center><abbr id='DF10048580'><dir id='DF10048580'><tfoot id='DF10048580'></tfoot><noframes id='DF10048580'>

    • <optgroup id='DF10048580'><strike id='DF10048580'><sup id='DF10048580'></sup></strike><code id='DF10048580'></code></optgroup>
        1. <b id='DF10048580'><label id='DF10048580'><select id='DF10048580'><dt id='DF10048580'><span id='DF10048580'></span></dt></select></label></b><u id='DF10048580'></u>
          <i id='DF10048580'><strike id='DF10048580'><tt id='DF10048580'><pre id='DF10048580'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:56229
          Suzanne KreiterGlobe staff

          The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

          But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

          advertisement

          Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          GSK’s asthma push continues as drug succeeds in Phase 3 trials
          GSK’s asthma push continues as drug succeeds in Phase 3 trials

          AkiraSuemori/APAnewasthmatreatmentthatcouldbeadministeredjustonceeverysixmonthshassucceededintwoPhas

          read more
          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more

          How to protect coverage of PrEP

          ApharmacistpoursTruvadapills,usedforPrEP,backintothebottleatapharmacyinSanAnselmo,Calif.JustinSulliv